Key result
Prophylactic low-dose aspirin reduced the incidence of pre-eclampsia compared to placebo in high-risk pregnant women with a previous history of the condition.
Why the study?
Pre-eclampsia causes pregnancy complications, but the effectiveness of prophylactic aspirin in preventing pre-eclampsia among pregnant women with a previous history of the condition needed evaluation.
Does aspirin 80 mg daily prevent pre-eclampsia in high-risk pregnant women?
RCT (n=260)
Double-blind
Randomized
No
Does aspirin 80 mg daily prevent pre-eclampsia in high-risk pregnant women?
Low-dose aspirin (80 mg daily) significantly reduces the incidence of pre-eclampsia in high-risk pregnant women, particularly those with a previous history of the condition.
Answers are grounded in this paper and cite their sources.
Supports aspirin 80 mg prophylaxis in high-risk pregnancies; confirms pre-eclampsia prevention in RCT evidence.
Background: Aspirin is considered a safe and secure prophylactic or preventative agent for the treatment of preeclampsia patients. Pre- eclampsia is developed in pregnant women which cause complications in their pregnancy due to high blood pressure and damage to other body organs. The incidence of Pre-eclampsia is 2-8% of pregnancies, but has a higher risk of about 10% in those females suffering from hypertension or autoimmune diseases. Aim: To know how effectively aspirin is used in preventing the pre-eclampsia in pregnant women who have had the previous history of preeclampsia. Methodology: A randomized controlled trial of aspirin and placebo was conducted. The women enrolled in this study have a gestational period of 6 to 32 weeks. All the women were administrated with 80 mg of placebo or aspirin daily. All the continuous and categorial variables were analyzed statistically and the results were presented as mean±S.D. and frequency(%) for these variables, respectively. Results: All the data was gathered from 260 women who were enrolled in this study. It showed that the occurrence of pre-eclampsia was higher in the placebo group as compared to aspirin group (4.1% vs. 1.6%, p=0004). However, in every risk group, the effects of placebo and aspirin were the same for women with hypertension, the incidence was 13.4% in aspirin and 15.7% in placebo and for women with diabetes, the incidence was 6.7% in aspirin and 6.6% in placebo; but for women with previous history of pre-eclampsia, the incidence was 1.6% in aspirin and 4.1% in placebo which was significantly different. Further, the incidence of pre-eclampsia with primary and secondary outcomes in aspirin and placebo were the same. Conclusion: Our research finding reveals that a low dose of aspirin had a considerable therapeutic effect in preventing pre-eclampsia in high-risk pregnant women.
No takes yet. Share an insight, caveat, or question.
Anjum et al. (2022) conducted an RCT in High risk for pre-eclampsia (n=260). Aspirin vs. Placebo was evaluated on Incidence of pre-eclampsia (p=0.004). Prophylactic low-dose aspirin reduced the incidence of pre-eclampsia compared to placebo in high-risk pregnant women with a previous history of the condition.
Synapse has enriched 10 related papers. Consider them for comparative context: